Produktbild: Melatonin, Neuroprotective Agents and Antidepressant Therapy

Melatonin, Neuroprotective Agents and Antidepressant Therapy

Fr. 277.00

inkl. gesetzl. MwSt., Versandkostenfrei


Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

20.07.2018

Abbildungen

XXV, 178 illus., 113 illus. in color., schwarz-weiss Illustrationen, farbige Illustrationen

Herausgeber

Francisco López-Muñoz + weitere

Verlag

Springer India

Seitenzahl

921

Maße (L/B/H)

25.4/17.8/4.8 cm

Gewicht

1957 g

Auflage

Softcover reprint of the original 1st ed. 2016

Sprache

Englisch

ISBN

978-81-322-3842-3

Beschreibung

Portrait

Prof.Venkataramanujan Srinivasan,Msc, Ph.D MAMS
SRI SATHYA SAI MEDICAL EDUCATIONAL AND RESEARCH FOUNDATION
An International Medical Sciences Research Study Center
“PrasanthiNilayam”, KOVAI, Coimbatore, Tamilnadu, INDIA

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

20.07.2018

Abbildungen

XXV, 178 illus., 113 illus. in color., schwarz-weiss Illustrationen, farbige Illustrationen

Herausgeber

Verlag

Springer India

Seitenzahl

921

Maße (L/B/H)

25.4/17.8/4.8 cm

Gewicht

1957 g

Auflage

Softcover reprint of the original 1st ed. 2016

Sprache

Englisch

ISBN

978-81-322-3842-3

Herstelleradresse

Libri GmbH
Europaallee 1
36244 Bad Hersfeld
DE

Email: gpsr@libri.de

Kundinnen und Kunden meinen

0 Bewertungen

Informationen zu Bewertungen

Zur Abgabe einer Bewertung ist eine Anmeldung im Konto notwendig. Die Authentizität der Bewertungen wird von uns nicht überprüft. Wir behalten uns vor, Bewertungstexte, die unseren Richtlinien widersprechen, entsprechend zu kürzen oder zu löschen.

Die Bewertungen sind nach Format, Anzahl Sterne und Datum sortiert.

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kund*innen durch Ihre Meinung

Kundinnen und Kunden meinen

0 Bewertungen filtern

  • Produktbild: Melatonin, Neuroprotective Agents and Antidepressant Therapy
  • History of pineal gland as neuroendocrine organ and discovery of melatonin.- Bibliometric study of scientific research on melatonin during the last 25 years.- Neuroimaging of the pineal gland. Focus on Primary Insomnia.- Melatonin: Basic and clinical aspects.- Melatonin and melatonin receptors in neuroprotection.- Melatonin supplementation in neurodegenerative diseases: Current status.- Therapeutic potential of melatonin in combination with other drugs against neurodegeneration.- Melatonin, a neuroprotective agent: relevance for stress induced neuropsychiatric disorders.- Melatonin, sleep, circadian rhythm and mood disorders.- Melatonin induces antidepressant-like behavior by promotion of hippocampal neurogenesis.- Association between melatonin and neuroimmune diseases.- Melatonin in clinical states of patients with fibromyalgia syndrome.- Melatonin's beneficial effects in hepatic injury.- Melatonin as a novel therapeutic agent against chemical warfare agents.- New galenic formulations of melatonin.- Melatonergic drug ramelteon in neurotherapeutics.- Melatonergic antidepressant agomelatine and its efficacy in depressive disorders.- Agomelatine, melatonin and depression.- Neuropsychological models of depression.- Chronobiology of mood disorders.- Bipolar disorders and biological rhythm.- Circadian clock genes and mood disorders.- Understanding the biologically adaptive side of mood disorders: a focus on affective temperaments.- Sleep abnormalities as diagnostic tool for major depressive disorder.- Depression: Correlations with thyroid hormones in major depressive disorder.- History of the discovery of antidepressant drugs.- Neurocognitive deficit in bipolar disorders.- Combination strategies in treatment-resistant depression.- Antidepressant drugs in elderly.- Antidepressant efficacy of escitalopram in major depressive disorder.- Antidepressant medications and suicide risk: What was the impact of FDA warning?.- Neurobiology and pharmacological prevention of suicidein mood disorders.- Antidepressants and anticonvulsants as adjuvant analgesics in chronic pain.- Genetic polymorphisms of cytochrome P450 enzymes and antidepressants.- Pharmacogenomics of antidepressant drugs.- Antidepressants modulate microglia beyond the neurotransmitters doctrine of mood disorders.- Brain-derived neurotrophic factor (BDNF) - TrkB signaling in depression: Biomarker and novel therapeutic target.- Targeting opioid receptors for innovative antidepressant therapies: rediscovering the opioid cure.- Prolactin and somatostatin responses to antidepressant therapy.- The role of vasopressin in anxiety and depression.- Ketamine: the glutamatergic antidepressant and its efficacy.- Acetylcholinergic nicotinic receptors as pharmacological targets for cognitive enhancement: emerging evidence from psychosis populations.-The glutamate mGluR5 receptor as a pharmacological target to enhance cognitive function: emerging evidence from psychosis models.- Corticotropin-releasing factor receptors as a potential target in the developments of antidepressant drugs.- Nitric oxide signaling in depression and antidepressant action.- The role of arrestins in the neuroprotective aspects of antidepressant drugs.- Antidepressant drugs and phosphodiesterases.- Effect of methylphenidate and atomoxetine on development of the brain.- S-Adenosyl-L-methionine for major depressive disorder.- The role of antiepileptic drugs in bipolar depression.- Melatonin and other neuroprotective agents target molecular mechanisms of disease in amyotrophic lateral sclerosis